FDA MedWatch

Reports of adverse effects in children who may have been unintentionally exposed to the drug through skin contact with women using this product.

Cases of serious, potentially fatal pneumonia associated with the IV antibacterial drug Cubicin.

Recall due to balloon inflation assembly that may not hold air

Product contains sibutramine; may increase blood pressure/pulse rate with risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, stroke.

Software and hardware problems associated with unexpected system loss of power, unintended system error messages, unresponsive touchscreens, and system setting and infusion performance problems.

Lab analyses found that certain batches of Vialipro contain Sulfoaildenafil, an analogue of Sildenafil.

Product found to contain undeclared N-Desmethyl Sibutramine and traces of Sibutramine.

Certain inhalers stolen from a distribution warehouse in 2009 have been found in some pharmacies. The safety and effectiveness of the stolen inhalers cannot be assured and they should not be used.

A recently published study suggested use of ARBs may be associated with a small increased risk of cancer.

Some tablets may not meet specification for isopropanol, which could affect therapeutic levels of the active ingredient.

Warning highlights the risk of severe liver injury and how this risk may be reduced.

Reports of life-threatening air or gas embolism occurring during or immediately after application of hemostatic drug or biological products.

Herbal product, sold as weight loss supplement, contains unlisted active pharmaceutical ingredients. Risk of serious side effects, especially in those with heart conditions.

New Risk Management Plan. Reports of serious side effects in patients using Qualaquin "off-label" for night time leg cramps.

UPDATED 07/08/2010. Recall expanded to include lots of 21 products of Benadryl, Tylenol, Childrens Tylenol, Tylenol PM and Motrin.

The firm received increasing numbers of complaints for false negative MRSA results. False negative could result in incorrect treatment or delay of care for patients with MRSA infection.

A power supply assembly failure can result in the inability to deliver defibrillation therapy.

Drug failed to demonstrate clinical benefit to patients enrolled in trials.

Product marketed as a dietary supplement for sexual enhancement contains the drug ingredient hydroxythiohomosildenafil, a chemical that may interact with prescription nitrates, and cause dangerously low blood pressure.

Potentially harmful product represented as “Generic Tamiflu”- tests revealed product does not contain oseltamivir, but cloxacillin, an antibiotic.